• Japanese
  • Korean
  • Chinese
Cover Image

Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022

GlobalData has released its new report, "Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Lyxumia (lixisenatide) is a fourth-to-market GLP-1 receptor agonist developed by Zealand Pharma and in-licensed to Sanofi. It was approved in the EU in February 2013, and is under review as a New Drug Application (NDA) by the FDA as of July 2013.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lyxumia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lyxumia for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Lyxumia performance
  • Obtain sales forecast for Lyxumia from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Diagnosis and Referrals
    • 4.1.2. Treatment Guidelines

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Lyxumia (lixisenatide)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Non-glycemic Benefits
  • 6.4. Safety

6.5. SWOT Analysis

  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Type 2Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. Drugs Included in Each Therapeutic Class
    • 7.4.4. Launch and Patent Expiry Dates
    • 7.4.5. General Pricing Assumptions
    • 7.4.6. Individual Drug Assumptions
    • 7.4.7. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst II - CVMD
    • 7.6.2. Therapy Director - CVMD and Infectious Disease
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Type 2 Diabetes
  • Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
  • Table 3: Treatment Guidelines for Type 2 Diabetes
  • Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
  • Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
  • Table 6: Product Profile - Lyxumia
  • Table 7: Lyxumia SWOT Analysis, 2012
  • Table 8: Global Sales Forecasts ($m) for Lyxumia, 2012-2022
  • Table 9: Key Launch Dates
  • Table 10: Key Patent Expiry Dates
  • Table 11: Number of High-Prescribing Physicians Surveyed

List of Figures

  • Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Show More
Pricing